Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in c-MET Mutated Endometrial Cancer
NCT04030429Phase 2Terminated
- Sponsor
- National Cheng Kung University Hospital
- Start
- Sep 2019
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in endometrial cancer (EC), sponsored by National Cheng Kung University Hospital. Started Sep 2019; status: terminated.
02
Drugs
crizotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04030429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030429.